Want to see ACET full AI Analyst Report?
Top Page
Adicet Bio
(NASDAQ:ACET)
Select Model
Select Model
Rating:51Neutral
Price Target:
$9.00
▲(15.53% Upside)
Action:Reiterated
Date:08/06/26
The score is held back primarily by weak financial performance (no meaningful revenue, large ongoing losses, and significant cash burn), partially offset by low leverage and currently constructive technical momentum. Valuation is difficult to support with a negative P/E and no dividend signal, while corporate events add only a small governance-stability positive.
Positive Factors
Allogeneic γδ T‑cell Platform
Adicet’s off-the-shelf γδ T‑cell approach is structurally advantaged versus autologous therapies: it can enable standardized manufacturing, faster patient access, and potential per-patient cost reductions. These attributes support scalable commercial potential and a broader addressable market if clinical proof emerges.
Negative Factors
No Meaningful Revenue
With effectively no commercial revenue, Adicet remains entirely reliant on development-stage progress and external financing. This structural absence of sales means the business model cannot self-fund operations, leaving long-term program continuity contingent on successful trials or repeat capital raises.
Read all positive and negative factors
Positive Factors
Negative Factors
Allogeneic γδ T‑cell Platform
Adicet’s off-the-shelf γδ T‑cell approach is structurally advantaged versus autologous therapies: it can enable standardized manufacturing, faster patient access, and potential per-patient cost reductions. These attributes support scalable commercial potential and a broader addressable market if clinical proof emerges.
Read all positive factors
Adicet Bio (ACET) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$85.16M
Dividend YieldN/A
Average Volume (3M)90.40K
Price to Earnings (P/E)―
Beta (1Y)1.96
Revenue GrowthN/A
EPS Growth27.27%
CountryUS
Employees102
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-11.45
Shares Outstanding9,348,236
10 Day Avg. Volume97,107
30 Day Avg. Volume90,404
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.36
Price to Sales (P/S)0.00
P/FCF Ratio-0.60
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$21.00Price Target Upside169.58% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-7.69
Revenue Forecast (FY)N/A
Adicet Bio Business Overview & Revenue Model
Company Description
Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen rece...
How the Company Makes Money
null...
Adicet Bio Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
56
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 24.99M | 9.73M |
| Gross Profit | -1.34M | -6.38M | 0.00 | 0.00 | 24.99M | 9.73M |
| EBITDA | -91.82M | -110.39M | -110.65M | -136.53M | -64.70M | -60.41M |
| Net Income | -98.97M | -116.80M | -117.12M | -142.66M | -69.79M | -62.00M |
Balance Sheet | ||||||
| Total Assets | 148.17M | 192.35M | 220.22M | 207.29M | 330.69M | 338.94M |
| Cash, Cash Equivalents and Short-Term Investments | 118.19M | 158.53M | 176.30M | 159.71M | 257.66M | 277.54M |
| Total Debt | 12.85M | 14.74M | 17.23M | 20.92M | 21.02M | 20.94M |
| Total Liabilities | 28.03M | 33.15M | 33.61M | 37.12M | 38.35M | 35.81M |
| Stockholders Equity | 120.14M | 159.21M | 186.61M | 170.18M | 292.34M | 303.13M |
Cash Flow | ||||||
| Free Cash Flow | -106.49M | -96.98M | -93.50M | -98.18M | -61.55M | -64.10M |
| Operating Cash Flow | -106.02M | -95.25M | -92.38M | -93.72M | -44.77M | -51.05M |
| Investing Cash Flow | 26.71M | 2.39M | -119.24M | -4.46M | -16.78M | -2.80M |
| Financing Cash Flow | 75.01M | 75.25M | 111.31M | 236.00K | 41.51M | 242.69M |
Adicet Bio Technical Analysis
Positive
7.79
Price Trends
8.37
Positive
7.93
Positive
8.45
Positive
Market Momentum
0.19
Negative
59.38
Neutral
69.85
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACET, the sentiment is Positive. The current price of 7.79 is below the 20-day moving average (MA) of 8.57, below the 50-day MA of 8.37, and below the 200-day MA of 8.45, indicating a bullish trend. The MACD of 0.19 indicates Negative momentum. The RSI at 59.38 is Neutral, neither overbought nor oversold. The STOCH value of 69.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ACET.
Adicet Bio Risk Analysis
Adicet Bio disclosed 24 risk factors in its most recent earnings report. Adicet Bio reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Adicet Bio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $59.20M | -0.74 | -68.98% | ― | ― | -26.14% | |
53 Neutral | $490.74M | -2.85 | -73.16% | ― | ― | -18.99% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $85.16M | -0.61 | -80.35% | ― | ― | 27.27% | |
47 Neutral | $71.66M | -2.90 | -201.43% | ― | ― | 33.86% | |
42 Neutral | $400.51M | -1.47 | 192.77% | ― | 49.94% | 44.76% |
* Healthcare Sector Average
ACET
Adicet Bio
7.93
-3.06
-27.86%
STRO
Sutro Biopharma
24.15
16.15
201.87%
PMVP
PMV Pharmaceuticals
1.18
-0.27
-18.62%
GANX
Gain Therapeutics
1.78
0.29
19.46%
IMMX
Immix Biopharma
10.06
7.67
320.92%
ARTV
Artiva Biotherapeutics, Inc.
11.58
8.94
338.64%
Adicet Bio Corporate Events
Executive/Board ChangesShareholder Meetings
Adicet Bio Stockholders Back Directors, Pay and Auditor
Positive
Jun 18, 2026
On June 17, 2026, Adicet Bio, Inc. held its 2026 Annual Meeting of Stockholders, where investors elected Jeffrey Chodakewitz, Steve Dubin and Michael Grissinger as Class II directors to serve three-year terms ending with the 2029 annual meeting. T...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.